Hikal starts construction of multiproduct API plant

Published: 28-Oct-2011
Manufacturing Ingredients

Will be operational by June 2012

Hikal, an Indian supplier of active ingredients and intermediates to the pharmaceutical industry, has started construction of a new multipurpose, multiproduct API plant, which will be operational by June 2012.

The flexible plant will be able to manufacture four APIs simultaneously under GMP and consists of two parallel streams running simultaneously with quick changeover capability.

The plant will also be able to accommodate 32 reactors with capacities ranging from 6m3 to 10m3, resulting in a total reactor volume of approximately 300m3.

A wide range of reactions will be carried out in the new plant, including nitration, liquid phase Oppenauer oxidation, Swern oxidation, Suzuki reaction, chiral synthesis, Mannich reaction, Friedel Craft reactions and more.

The firm says the reactors will be a combination of stainless steel and glass lined. Equipment for isolation and drying such as agitated nutsch filters, centrifuges and various types of dryers will also be installed.

Hikal has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Bangalore (Jigani), including an r&D centre and a dedicated contract research facility, Acoris Research, in Pune.

See more

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Read more
Indian ingredients manufacturer will ramp up new products under validation

Trending Articles

  1. Echo MS+ integration enhances high-throughput mass spectrometry SCIEX expands compatibility with the ZenoTOF 8600 system to deliver greater sensitivity and automation capabilities
  2. Drug-loaded pellets: unlocking flexible oral dosage design with modern pelletisation technologies Produced using advanced extrusion–spheronisation technologies such as GEA’s NICA systems, drug-loaded pellets are gaining traction as a flexible and scalable oral solid dosage platform that enhances release control, patient outcomes and manufacturing efficiency
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Automated visual inspection: reducing false rejects with intelligent bubble masking This article explores how intelligent bubble masking in automated visual inspection systems can significantly reduce false rejects in biopharmaceutical manufacturing by accurately distinguishing harmless bubbles from harmful particles
  4. CARBOGEN AMCIS and Celonic unveil integrated ADC development platform at World ADC London 2026 The strategic alliance combines biologics and highly potent payload capabilities to streamline ADC development and manufacturing
  5. BASF appoints president of care chemicals

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Indian ingredients manufacturer will ramp up new products under validation
Media

Acoris and c-LEcta to develop synthetic routes for chiral compounds

<p>Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.</p>
Ingredients

Hikal signs API contract manufacturing agreement with Pfizer

<p>Indian outsourcing company Hikal has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (APIs) with Pfizer. Terms of the agreement were not disclosed.</p>
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Manufacturing

GEA opens new technology centre in Germany

The opening of the new technology centre for pharmaceutical freeze-drying systems will strengthen the supplier's position in the growing pharmaceutical applications market
Manufacturing

Avoiding product degradation with a low-temperature, vacuum cake dryer

High-performance chemicals often lose efficacy when exposed to heat. Active pharmaceutical ingredients (APIs), fine chemical intermediates, and biologically derived materials are subject to product degradation and can transform, or lose potency under high drying temperatures. This thermal sensitivity demands precise control to maintain molecular stability and ensure product quality
Manufacturing

Cutting-edge customer projects - Specialised systems for multiple sectors

As specialists in laboratory and process chemistry equipment solutions, Labtex have expertise in designing, manufacturing, and installing customised systems for a diverse range industries and disciplines – including chemical manufacturing, drug development, and metals recovery
Subscribe now